# Phase 5.2.3 Sub-Milestone 4.4: Regimen Integration & Verification Report

**Document Version:** 1.0  
**Status:** Sub-Milestone 4.4 Complete  
**Date:** 2026-10-31  
**Scope:** Medication Regimen Integration, Safety Edge-Case Fixtures, Review Gate Conformance, and Verification Baseline Preservation  

---

## 1. Executive Summary & Boundaries

Sub-Milestone 4.4 integrates and verifies the medication regimen mapping capabilities established in Sub-Milestones 4.1 through 4.3. All changes and verifications were conducted strictly within authorized boundaries:

1. **Security & Governance Blocker Enforced:**  
   The unresolved multi-hop Four-Eyes ancestry vulnerability remains an **absolute clinical export blocker**. As mandated, `src/clindoc/review/service.py` and `src/clindoc/services/fhir_export.py` were maintained **strictly frozen**. No weakening, bypassing, or silent waiving was introduced. In-memory `ACCEPTED` claims without verified cryptographic audit ledger proofs fail closed with `SUPPRESSED_UNVERIFIED_AUDIT_LEDGER`.
2. **Production Code Scope Restriction:**  
   Production modifications were strictly confined to [src/clindoc/fhir/mapper.py](file:///d:/daa/src/clindoc/fhir/mapper.py) to resolve REQ-44-03 (duplicate duration token occurrence matching) and enforce REQ-44-01 / W-2 fail-closed isolation (`__no_anchor__` suppression). All other core modules (`medication_association.py`, `segmentation.py`, `deterministic.py`, `verify/stage_a.py`, `ocr/layout.py`, `fhir/constants.py`, vocabularies, configurations) remained strictly frozen.
3. **REQ-44-04 Narrative Transition Context Reconciled:**  
   Empirical analysis and unit tests confirmed that existing `"Then "` prefixing logic in `_build_regimen_dosages` is implemented and sufficient to preserve sequential phase continuity and prevent combined dose distortion.
4. **Safety & Conformance Regression Fixtures Added:**  
   Seven dedicated integration tests were implemented in [tests/test_phase523_milestone4_4.py](file:///d:/daa/tests/test_phase523_milestone4_4.py), achieving 100% pass rate (7/7) alongside the full 114-test medication/FHIR suite.
5. **Baseline & Denominator Preservation:**  
   All evaluation benchmark denominators remain 100% frozen with zero drift. The repository-wide test baseline preserved the exact 5 historical pre-existing failures with zero newly introduced regressions across 1,459 tests.
6. **Git State Integrity:**  
   Zero git staging, commits, pushes, resets, cleans, or discards were executed. All prior workspace changes remain intact.
7. **Clinical Disclaimer:**  
   **No claim of clinical readiness or real-world validation is made.** This sub-milestone achieves algorithmic and FHIR R4B structural conformance only. Multi-hop Four-Eyes security remediation requires separate authorization.

---

## 2. Workstream Breakdown & Deliverables

### Workstream 1: Safety & Edge-Case Fixtures

#### 1.1 W-2 Multi-Page Medication Split Fail-Closed Isolation (REQ-44-01)
- **Problem:** When a medication name anchor appears at the bottom of Page 1, but its continuation dose and frequency appear on Page 2 without a local drug anchor, naive processing could either cause the Page 2 dose to cross page boundaries to attach to Page 1, or cause the unanchored Page 2 dose to be emitted as an orphan order (`"Unspecified Medication"`).
- **Remediation & Mapping Rule:**
  - Upstream segmentation partitions unanchored tokens on Page 2 into `group_id = "__no_anchor__"`.
  - In [src/clindoc/fhir/mapper.py](file:///d:/daa/src/clindoc/fhir/mapper.py), `claims_to_fhir_bundle` explicitly suppresses `grp_key == "__no_anchor__"` or `grp_key.startswith("__no_anchor")`.
  - Verified via `test_w2_multipage_medication_split_fail_closed`: Page 1 Lisinopril is emitted without Page 2 dose contamination (`doseAndRate is None`), and Page 2 continuation dose (20 mg) is discarded at the mapper boundary.

#### 1.2 Duplicate Duration Token Matching in Shared Evidence Spans (REQ-44-03)
- **Problem:** In multi-step tapers such as `"Prednisone 40 mg daily for 2 weeks, then 20 mg daily for 2 weeks, then 10 mg daily"`, multiple duration claims (`"2 weeks"`) share a single evidence span where `char_start == 0`. Prior matching using simple substring index collapsed both duration claims to the first occurrence index ($pos = 27$), causing phase window misattribution.
- **Remediation:**
  - Updated `_get_claim_pos(claim, ev_map, occurrence_idx=0)` in [src/clindoc/fhir/mapper.py](file:///d:/daa/src/clindoc/fhir/mapper.py) to track occurrence indices via `re.finditer(re.escape(val_str), text, re.IGNORECASE)`.
  - Updated `_build_regimen_dosages` to sort durations by occurrence index and apply index parity fallback when `len(sorted_durs) == len(sorted_doses)`.
  - Verified via `test_req_44_03_shared_evidence_duplicate_duration_matching`: Phase 1 resolves to 2 weeks UCUM `wk` boundsDuration ($pos = 27$), Phase 2 resolves to 2 weeks UCUM `wk` boundsDuration ($pos = 57$), and Phase 3 remains an open-ended maintenance phase with no duration.

#### 1.3 Narrative Transition Context Sufficiency (REQ-44-04)
- **Reconciliation:**
  - Evaluated existing implementation of `_build_regimen_dosages` lines 504–514.
  - Initial sequential phase generates: `"{med_name} {dose_str} {freq_str} {dur_str}"` (e.g. `"Prednisone 20 mg daily for 5 days"`).
  - Subsequent sequential phases ($idx > 0$) automatically receive the prefix `"Then {dose_str} {freq_str} {dur_str}"` (e.g. `"Then 10 mg daily for 5 days"`, `"Then 5 mg daily"`).
  - Verified via `test_req_44_04_narrative_sig_transition_context_sufficiency`: Narrative transitions are fully preserved, duration bounds are retained, and dose quantities are never summed across instructions (e.g. 35 mg total is never emitted as a single dose). Existing `"Then "` prefixing is sufficient for human clinical interpretation without downstream dose distortion.

---

### Workstream 2: End-to-End Regimen Pipeline Integration

#### 2.1 Split-Dosing Schema Conformance
- Executed `test_split_dosing_e2e_bundle_and_fhir_validator` on `"Carvedilol 12.5 mg every morning and 25 mg at bedtime."`.
- **Validation Results:**
  - Passed `FHIRValidator.validate_bundle(bundle)` with 0 schema errors.
  - Emitted `MedicationRequest` with two concurrent `dosageInstruction` elements, each having `sequence: 1`.
  - Timing codes accurately populated: morning (`timing.repeat.when = ["MORN"]`), bedtime (`timing.repeat.when = ["NIGHT"]`).
  - Both instructions retain element-level provenance (`EXT_CLAIM_PROVENANCE`) linking dose quantities back to source claim IDs (`c-d1` and `c-d2`).

#### 2.2 Sequential Taper Statement Conformance
- Executed `test_sequential_taper_medication_statement_e2e_validator` on progress note narrative `"Methylprednisolone 16 mg daily for 3 days, then 8 mg daily."`.
- **Validation Results:**
  - Passed `FHIRValidator.validate_bundle(bundle)` with 0 schema errors.
  - Successfully mapped to `MedicationStatement` with two `dosage` elements having `sequence: 1` and `sequence: 2`.
  - Phase 1 maps `boundsDuration` (value `3`, unit `days`, code `d`, system `http://unitsofmeasure.org`). Phase 2 maintenance maps `repeat: None`.

---

### Workstream 3: Gate 9 & Human Review Contract Integration

#### 3.1 Four-Eyes Export Blocker Inviolability
- Verified via `test_four_eyes_ancestry_blocker_remains_active`:
  - Instantiated `FHIRExportService(enforce_audit_evidence=True)`.
  - Evaluated claim having in-memory `review_state: "ACCEPTED"` but lacking an immutable, verified audit ledger entry.
  - Export service failed closed: `is_eligible == False`, reason `SUPPRESSED_UNVERIFIED_AUDIT_LEDGER`.
  - Confirmed that `src/clindoc/review/service.py` and `src/clindoc/services/fhir_export.py` remain frozen and impervious to unverified state manipulation.

#### 3.2 Competing Candidate Metadata Shadowing
- Verified via `test_competing_candidate_shadowing_provenance_emitted`:
  - When alternate OCR candidate exists (e.g. 6.25 mg vs 6.250 mg), the winning slot candidate is selected deterministically based on confidence and length.
  - Non-selected candidate is tracked in `grp_med_shadowed` and exported as an `EXT_COMPETING_CANDIDATE` FHIR extension on the medication resource containing `selectedClaimId`, `competingClaimId`, and `competingValue`.

---

### Workstream 4: Regression Verification & Preservation

#### 4.1 Focused & Regimen Test Suites
- **Sub-Milestone 4.4 Focused Suite:**
  - Command: `pytest tests/test_phase523_milestone4_4.py -v`
  - Result: **7 passed in 0.11s** (100% pass).
- **Combined Medication, Provenance & Export Suite (114 Tests):**
  - Command: `pytest tests/test_phase523_milestone4_4.py tests/test_phase523_milestone4_3.py tests/test_phase523_milestone4_2.py tests/test_phase523_milestone4_1.py tests/test_canonical_fhir_mapping.py tests/test_fhir_export.py tests/test_phase44_diagnostic_report_grouping.py tests/test_phase441_conformance_audit.py tests/test_phase442_export_integrity.py`
  - Result: **114 passed in 2.66s** (100% pass).

#### 4.2 Benchmark Denominators
- Ground truth benchmarks in `external_eval/` and `data/ground_truth` remain 100% frozen.
- Denominators for both the 12-doc frozen baseline and 60-doc expanded benchmark are untouched with zero metric drift.

#### 4.3 Full Repository Test Baseline
- Total repository test count: **1,459 tests**.
- Passing tests: **1,454 passed**.
- Failures: **Exactly 5 pre-existing historic baseline failures preserved** with zero newly introduced regressions:
  1. `tests/test_cli.py::test_cli_unsupported_extension_fails`
  2. `tests/test_document_ingestion.py::test_13_unreadable_invalid_document_handling`
  3. `tests/test_m2_v2_corrections.py::test_lab_flag_v2_generation`
  4. `tests/test_section_detection_production.py::TestSectionDetectionDisabledParity::test_disabled_mode_extracts_headers_identically_to_baseline`
  5. `tests/test_vllm_deployment.py::test_client_code_does_not_disable_tls_verification`

---

## 3. Summary of Files Changed

| File Path | Type | Nature of Change |
|---|---|---|
| [src/clindoc/fhir/mapper.py](file:///d:/daa/src/clindoc/fhir/mapper.py) | Production Code | (1) Added `occurrence_idx` tracking with regex iteration in `_get_claim_pos` for duplicate-duration disambiguation (REQ-44-03). (2) Added index parity fallback in `_build_regimen_dosages`. (3) Added `__no_anchor__` group suppression in `claims_to_fhir_bundle` for W-2 fail-closed isolation. |
| [tests/test_phase523_milestone4_4.py](file:///d:/daa/tests/test_phase523_milestone4_4.py) | Test Suite | Added 7 comprehensive regression and integration tests covering W-2 split isolation, duplicate duration matching, narrative SIG sufficiency, split-dosing validator conformance, taper statement validator conformance, competing candidate shadowing, and Four-Eyes Gate 9 fail-closed verification. |
| [phase523_milestone432_audit_reconciliation_and_m44_plan.md](file:///d:/daa/phase523_milestone432_audit_reconciliation_and_m44_plan.md) | Documentation | Updated with user clarifications, explicitly recording Four-Eyes export blocker, REQ-44-04 sufficiency, and workstream definitions. |

---

## 4. Unresolved Risks & Next Phase Requirements

1. **Multi-Hop Four-Eyes Ancestry Vulnerability:**  
   As documented throughout Phase 5.2.3, the review ledger ancestry check vulnerability remains unresolved and requires dedicated architectural remediation before clinical export authorization can be granted.
2. **Receiving-EHR Taper Discrepancies:**  
   While `Dosage.sequence` and `boundsDuration` conform structurally to FHIR R4B, receiving EHRs exhibit non-standardized ingestion behavior for multi-phase orders. Narrative `Dosage.text` (`"Prednisone ... Then ..."`) remains the primary patient safety defense.
3. **Workspace Isolation:**  
   All changes remain uncommitted and unstaged in working directory `d:\daa`.
